Cremer PC, Kumar A, Kontzias A, et al. Complicated pericarditis: understanding risk factors and pathophysiology to inform imaging and treatment. J Am Coll Cardiol. 2016;68:2311–28.

PubMed  Article  Google Scholar 

Imazio M, Brucato A, Adler Y. A randomized trial of colchicine for acute pericarditis. N Engl J Med. 2014;370:781.

CAS  PubMed  Article  Google Scholar 

Imazio M, Bobbio M, Cecchi E, et al. Colchicine in addition to conventional therapy for acute pericarditis: results of the COlchicine for acute PEricarditis (COPE) trial. Circulation. 2005;112:2012–6.

CAS  PubMed  Article  Google Scholar 

Imazio M, Brucato A, Rampello S, et al. Management of pericardial diseases during pregnancy. J Cardiovasc Med (Hagerstown). 2010;11:557–62.

Article  Google Scholar 

Chiabrando JG, Bonaventura A, Vecchié A, et al. Management of acute and recurrent pericarditis: JACC state-of-the-art review. J Am Coll Cardiol. 2020;75:76–92.

CAS  PubMed  Article  Google Scholar 

Imazio M, Belli R, Brucato A, et al. Efficacy and safety of colchicine for treatment of multiple recurrences of pericarditis (CORP-2): a multicentre, double-blind, placebo-controlled, randomised trial. Lancet. 2014;383:2232–7.

CAS  PubMed  Article  Google Scholar 

Chetrit M, Xu B, Kwon DH, et al. Imaging-guided therapies for pericardial diseases. JACC Cardiovasc Imaging. 2020;13:1422–37.

PubMed  Article  Google Scholar 

Imazio M, Adler Y. Treatment with aspirin, NSAID, corticosteroids, and colchicine in acute and recurrent pericarditis. Heart Fail Rev. 2013;18:355–60.

CAS  PubMed  Article  Google Scholar 

van Kempen TS, Wenink MH, Leijten EF, Radstake TR, Boes M. Perception of self: distinguishing autoimmunity from autoinflammation. Nat Rev Rheumatol. 2015;11:483–92.

PubMed  Article  CAS  Google Scholar 

Swanson KV, Deng M, Ting JP. The NLRP3 inflammasome: molecular activation and regulation to therapeutics. Nat Rev Immunol. 2019;19:477–89.

CAS  PubMed  PubMed Central  Article  Google Scholar 

Kaneko N, Kurata M, Yamamoto T, Morikawa S, Masumoto J. The role of interleukin-1 in general pathology. Inflamm Regen. 2019;39:12.

PubMed  PubMed Central  Article  CAS  Google Scholar 

Park H, Bourla AB, Kastner DL, Colbert RA, Siegel RM. Lighting the fires within: the cell biology of autoinflammatory diseases. Nat Rev Immunol. 2012;12:570–80.

CAS  PubMed  PubMed Central  Article  Google Scholar 

McGonagle D, McDermott MF. A proposed classification of the immunological diseases. PLoS Med. 2006;3: e297.

PubMed  PubMed Central  Article  CAS  Google Scholar 

Martinon F, Pétrilli V, Mayor A, Tardivel A, Tschopp J. Gout-associated uric acid crystals activate the NALP3 inflammasome. Nature. 2006;440:237–41.

CAS  PubMed  Article  Google Scholar 

Duewell P, Kono H, Rayner KJ, et al. NLRP3 inflammasomes are required for atherogenesis and activated by cholesterol crystals. Nature. 2010;464:1357–61.

CAS  PubMed  PubMed Central  Article  Google Scholar 

Muruve DA, Pétrilli V, Zaiss AK, et al. The inflammasome recognizes cytosolic microbial and host DNA and triggers an innate immune response. Nature. 2008;452:103–7.

CAS  PubMed  Article  Google Scholar 

Cantarini L, Rigante D, Merlini G, et al. The expanding spectrum of low-penetrance TNFRSF1A gene variants in adults presenting with recurrent inflammatory attacks: clinical manifestations and long-term follow-up. Semin Arthritis Rheum. 2014;43:818–23.

CAS  PubMed  Article  Google Scholar 

Ozen S, Demirkaya E, Amaryan G, et al. Results from a multicentre international registry of familial Mediterranean fever: impact of environment on the expression of a monogenic disease in children. Ann Rheum Dis. 2014;73:662–7.

PubMed  Article  Google Scholar 

Kees S, Langevitz P, Zemer D, Padeh S, Pras M, Livneh A. Attacks of pericarditis as a manifestation of familial Mediterranean fever (FMF). QJM. 1997;90:643–7.

CAS  PubMed  Article  Google Scholar 

Yu JW, Wu J, Zhang Z, et al. Cryopyrin and pyrin activate caspase-1, but not NF-kappaB, via ASC oligomerization. Cell Death Differ. 2006;13:236–49.

CAS  PubMed  Article  Google Scholar 

Booty MG, Chae JJ, Masters SL, et al. Familial Mediterranean fever with a single MEFV mutation: where is the second hit? Arthritis Rheum. 2009;60:1851–61.

CAS  PubMed  PubMed Central  Article  Google Scholar 

Dinarello CA, Chusid MJ, Fauci AS, Gallin JI, Dale DC, Wolff SM. Effect of prophylactic colchicine therapy on leukocyte function in patients with familial Mediterranean fever. Arthritis Rheum. 1976;19:618–22.

CAS  PubMed  Article  Google Scholar 

Leung YY, Yao Hui LL, Kraus VB. Colchicine-Update on mechanisms of action and therapeutic uses. Semin Arthritis Rheum. 2015;45:341–50.

CAS  PubMed  PubMed Central  Article  Google Scholar 

Ben-Chetrit E, Levy M. Colchicine prophylaxis in familial Mediterranean fever: reappraisal after 15 years. Semin Arthritis Rheum. 1991;20:241–6.

CAS  PubMed  Article  Google Scholar 

Rodriguez de la Serna A, Guindo Soldevila J, Marti Claramunt V, Bayes de Luna A. Colchicine for recurrent pericarditis. Lancet 1987;330(8574):1517.

Guindo J, Rodriguez de la Serna A, Ramió J et al. Recurrent pericarditis. Relief with colchicine. Circulation 1990;82:1117–20.

Adler Y, Zandman-Goddard G, Ravid M, et al. Usefulness of colchicine in preventing recurrences of pericarditis. Am J Cardiol. 1994;73:916–7.

CAS  PubMed  Article  Google Scholar 

Millaire A, Ducloux G. Treatment of acute or recurrent pericarditis with colchicine. Circulation. 1991;83:1458–9.

CAS  PubMed  Article  Google Scholar 

Imazio M, Brucato A, Cemin R, et al. Colchicine for recurrent pericarditis (CORP): a randomized trial. Ann Intern Med. 2011;155:409–14.

PubMed  Article  Google Scholar 

Mauro AG, Bonaventura A, Vecchié A, et al. The role of NLRP3 inflammasome in pericarditis: potential for therapeutic approaches. JACC Basic Transl Sci. 2021;6:137–50.

PubMed  PubMed Central  Article  Google Scholar 

Granowitz EV, Porat R, Mier JW, et al. Pharmacokinetics, safety and immunomodulatory effects of human recombinant interleukin-1 receptor antagonist in healthy humans. Cytokine. 1992;4:353–60.

CAS  PubMed  Article  Google Scholar 

Dinarello CA. Interleukin-1 in the pathogenesis and treatment of inflammatory diseases. Blood. 2011;117:3720–32.

CAS  PubMed  PubMed Central  Article  Google Scholar 

Yang BB, Baughman S, Sullivan JT. Pharmacokinetics of anakinra in subjects with different levels of renal function. Clin Pharmacol Ther. 2003;74:85–94.

CAS  PubMed  Article  Google Scholar 

Yang BB, Gozzi P, Sullivan JT. Pharmacokinetics of anakinra in subjects of heavier vs. lighter body weights. Clin Transl Sci. 2019;12:371–8.

CAS  PubMed  PubMed Central  Article  Google Scholar 

Buckley LF, Viscusi MM, Van Tassell BW, Abbate A. Interleukin-1 blockade for the treatment of pericarditis. Eur Heart J Cardiovasc Pharmacother. 2018;4:46–53.

PubMed  Article  Google Scholar 

Chakraborty A, Tannenbaum S, Rordorf C, et al. Pharmacokinetic and pharmacodynamic properties of canakinumab, a human anti-interleukin-1β monoclonal antibody. Clin Pharmacokinet. 2012;51:e1-18.

CAS  PubMed  PubMed Central  Article  Google Scholar 

Anthony C, Chetrit M, Lo Presti S, Klein A. IL-1 Trap Rilonacept for Recurrent Pericarditis: RHAPSODY Study. ACC.org: American College of Cardiology, 2021.

Autmizguine J, Cohen-Wolkowiez M, Ilowite N, Investigators R. Rilonacept pharmacokinetics in children with systemic juvenile idiopathic arthritis. J Clin Pharmacol. 2015;55:39–44.

CAS  PubMed  Article  Google Scholar 

Radin A, Marbury T, Osgood G, Belomestnov P. Safety and pharmacokinetics of subcutaneously administered rilonacept in patients with well-controlled end-stage renal disease (ESRD). J Clin Pharmacol. 2010;50:835–41.

CAS  PubMed  Article  Google Scholar 

Sánchez-Félix M, Burke M, Chen HH, Patterson C, Mittal S. Predicting bioavailability of monoclonal antibodies after subcutaneous administration: Open innovation challenge. Adv Drug Deliv Rev. 2020;167:66–77.

PubMed  Article  CAS  Google Scholar 

Regeneron Rilonacept: Summary of Product Characteristics. European Medicines Agency, 2012.

Wikén M, Hallén B, Kullenberg T, Koskinen LO. Development and effect of antibodies to anakinra during treatment of severe CAPS: sub-analysis of a long-term safety and efficacy study. Clin Rheumatol. 2018;37:3381–6.

PubMed  Article